👀👀👀
The Department of Justice filed a brief opposing a drug testing industry group and a pharmaceutical company's motion to pause cannabis rescheduling—pointing out that they have "pocketbook interests served by keeping all marijuana in schedule I."
https://t.co/OJ1zPqTe28
As President Trump has emphasized, debanking has hurt legal businesses across the country.
I reintroduced the SAFE Banking Act to keep our communities safe by ensuring state-legal businesses have access to the financial services they need to succeed.
https://t.co/vOvVeebpOR
@rivers_kim@Trulieve Thanks for killing the uplist momentum. From your stock sale to firing and then rehiring the President - amateur hour to say the least.
I’ve held your stock and continually bought more for the past 5 years - worst financial decision I’ve ever made.
A U.S. cannabis company has joined the New York Stock Exchange for the first time in history. Trulieve, a Florida-based operator, has made history as the first American cannabis business to trade on the NYSE, representing a major milestone in the industry’s acceptance by regulators, investors, and the scientific community.
For decades, marijuana’s classification as a Schedule I substance under federal law created significant obstacles for cannabis companies. Despite the rapid growth of medical and recreational markets across the country, most U.S. cannabis firms were barred from major American stock exchanges and were forced to list on smaller over-the-counter markets or move to Canadian exchanges.
That landscape is now shifting. The listing comes after the federal government rescheduled medical marijuana from Schedule I to Schedule III. Schedule I drugs are defined as having no accepted medical use and high potential for abuse (including substances like heroin and LSD). Schedule III substances, by contrast, have recognized medical applications and face fewer regulatory restrictions.
While this move does not legalize cannabis federally, recreational use remains illegal at the national level, it carries important scientific and financial consequences.
Researchers have long maintained that Schedule I restrictions severely limited rigorous clinical studies on cannabis. Scientists faced heavy bureaucratic hurdles when attempting to study its medical potential, optimal dosing, long-term effects, and interactions with other drugs.
With the new classification, universities and research institutions are expected to pursue more comprehensive clinical trials. This could finally produce stronger, evidence-based data on cannabis’s effectiveness for conditions such as chronic pain, epilepsy, and various neurological disorders.
For investors, Trulieve’s NYSE listing represents a clear signal that cannabis is entering mainstream financial markets. For the scientific community, it opens the door to studies that were previously extremely difficult to conduct.
Regardless of one’s stance on marijuana legalization, it is becoming evident that the future of cannabis will be shaped increasingly by scientific research and empirical data, rather than politics alone.
🇺🇸 Trulieve ($TRLV) is now trading on the NYSE.
It's the first major U.S. cannabis operator to secure a listing on a premier U.S. exchange: a milestone many thought was still years away.
The cannabis industry just took a major step toward the financial mainstream.
Writer: Val
@AlderLaneEggs@Bkov9@rivers_kim Constantly talking shit about people that have never done anything to you (and only helped this industry’s cause) is a very feminine trait. I think you need some TRT or maybe just shut up - it’s getting ridiculous.
$TCNNF - The Single Biggest Cannabis Catalyst in Years Is Rapidly Approaching 2 Marijuana Stocks to Buy Now
2026-06-07 00:35:00 ET A sea change is taking place for cannabis companies , one that will have an enormous benefit for the industry. … https://t.co/cukTu6N587